

Oculopatie Ereditarie in Italia nel Pinscher e nello Schnauzer

Dr. Adolfo Guandalini, PhD, Dipl.ECVO,, DIU Chir. VitreoRetinica
Membro ECVO HED Committee
Chairman panel Italiano Diplomati ECVO
CVS, Roma

Dr. Domenico Multari, PhD, SMCPA,
Chairman panel FSA
Fontane di Villorba, Treviso

Dr. Michela Quarta, PhD,
Bologna

SOMMARIO

- Introduzione
- Descrizione delle Malattie osservate più frequentemente nelle nostre razze in Italia
- Presentazione nuove malattie (PRA Gigante e Nano) con relativi test genetici
- Comparazione dati Italiani (Panel ECVO italiano e panel FSA) vs. dati esteri (Panel ECVO – D,S,A,DK,NO-, Svezia, Finlandia, USA)
- Visita oculistica e certificazioni presenti in Italia
- Condotta d'allevamento consigliata rispetto alle Malattie riscontrate più frequentemente in Italia
- Eventuali domande

Malattie Oculari

- *Congenite* : (per definizione presenti alla nascita) spesso *ereditarie* o con predisposizione di razza;
- *Non congenite (acquisite)*: *ereditarie* (per definizione malattie di sviluppo, compaiono dopo la nascita);
- *(Acquisite non ereditarie)*.

Malattie Oculari ereditarie

- “Hereditary Eye Diseases” (KP-HED);
- Known HED: (K-HED), di provata ereditarietà, ovvero è stata identificata la **mutazione** genetica ed esiste un test genetico disponibile (sono ancora pochi e non per tutte le malattie);
- Presumed HED: (P-HED), di presunta (ma non certa) ereditarietà, perchè non è stata ancora identificata la mutazione genetica e non è quindi disponibile un test genetico affidabile.

Quando una malattia può essere considerata ereditaria in una determinata razza?


- Quando la frequenza in quella razza è più alta che in altre;
- Quando la frequenza aumenta nella medesima razza;
- Quando la frequenza è più grande in soggetti imparentati;
- Quando ha aspetto e localizzazione particolari;
- Quando ha età di insorgenza e progressione particolari;
- Quando è uguale a patologie dimostrate ereditarie in altre razze;
- Quando si suppone una base genetica, ma non è stata individuata la mutazione.


Perché attuare un programma di prevenzione e controllo della malattie oculari ereditarie?

- Per ridurre l'incidenza di malattie oculari gravi e spesso invalidanti;
- Per migliorare il benessere dei nostri animali;
- Per fornire maggior garanzia agli acquirenti;
- Per migliorare il “pool” genetico di razza;
- Per elevare la qualità dei soggetti allevati;
- Per bloccare la diffusione di malattie oculari gravi ed emergenti.


Come attuare un programma di prevenzione e controllo della malattie oculari ereditarie?

- **Sottoporre a visita oculistica specialistica tutti i soggetti (adulti) destinati alla riproduzione (esame da ripetere annualmente);**
- **Associare alla visita la richiesta di esecuzione di test specifici genetici disponibili per ogni razza presso laboratori accreditati (una volta sola nella vita)**;
- **Non riprodurre i soggetti affetti (anche se di pregio!) e, per alcune patologie gravi, anche i figli di tali soggetti**;
- **Sterilizzare (o comunque **NON utilizzare**) i soggetti malati.**






Cristallino (Lente)




Retina

Atresia punto lacrimale




Persistenza Membrana Pupillare (PPM)

- Alta incidenza (>2-6 sett);
- Da segni clinici inosservati fino a gravi deficit visivi!
- **PPM iride-iride;**
- PPM iride-cornea;
- PPM iride-lente.



PPM-Persistenza Membrana Pupillare



Cataratta (ereditaria)

- **Nel cane spesso cataratte genetiche**; molte razze colpite, età variabile; evolutive e non evolutive; sempre **esclusione** dalla riproduzione!;
- 160 razze con sospetta ereditarietà (tratto autosomico recessivo semplice);
- **solo un gene identificato (HSF4).**
- Nell'uomo la maggior parte delle cataratte ereditarie sono congenite, mentre nel cane compaiono prevalentemente in età giovanile o adulta.

Ereditarietà: HSF4

- **Staffordshire Bull Terrier**: autosomico recessivo;
- **Boston Terrier**: autosomico recessivo (f. giovanile);
- **Bouledogue Francese**: **autosomico recessivo (?)**;
- Test genetico disponibile (HSF4-1);
- Pastore Australiano: test genetico disponibile (HSF4-2)
- **“””NON ESISTONO TEST GENETICI PER LA CATARATTA PER SCHNAUZER E PINSCHER”””**
- **Non riprodurre soggetti malati!**

CATARATTA


CATARATTA SUBCAPSULARE POLARE POSTERIORE. SCHNAUZER MEDIO



Cataratta subcaps. Pol. Post. OU; Riesenschнауzer



Cataratta subcaps. Pol. Post. OU; Riesenschнауzer



Cataratta (Congenita)

- *Definizione*: Opacità della lente;
- *Diagnosi*: **tra la nascita e le 8 sett. di vita;**
- *Localizzazione*: opacità nucleare fetale (non evolutiva); a volte anche corticale anteriore e posteriore (unilaterale o bilaterale, evolutiva).


Cataratta congenita Schnauzer Nano



- ***Schnauzer nano***: ereditarietà recessiva;
- Opacità nucleare o subcapsulare posteriore bilaterale (*rapidamente evolutiva*), spesso associata a microftalmo (lieve).



PHPV/PHTVL 1° GRADO



PHPV/PHTVL 2°-6° GRADO




Displasia Retinica



- Anomala differenziazione retinica durante il suo sviluppo con proliferazione di alcuni suoi elementi; formazione di “rosette” (rosettes) con/senza “pieghe” (folds);
- Tre forme cliniche;
- Ereditarietà in molte razze;

Displasia Retinica



- “Retinal folds”: strie bianche o grigie singole o multiple, rotonde, ovali, triangolari, lineari o curvilinee, a V o Y uni o bilaterali, zona tappetale o non tappetale (displasia focale o multifocale; 30 razze);
- “Forma geografica”: area irregolare con zone retiniche più sottili insieme a zone di retina più spessa (displasia geografica; 11 razze);
- “Forma totale o completa” (displasia retinica completa con distacco o “non attacco”).




Displasia Retinica MF/Geografica



Displasia Retinica MF, Riesenschnauzer



Displasia Retinica Geografica, Zwergpinscher



Displasia retinica

- Forme **ereditarie** (più comuni);
- *Test genetico* per alcune forme (RD-OSD); **““QUESTO TEST E' INUTILE PER LE NOSTRE RAZZE; QUINDI **NON ESISTONO TEST GENETICI PER LE RAZZE SCHNAUZER E PINSCHER””**”**



Inherited retinal dysplasia and persistent hyperplastic primary vitreous in Miniature Schnauzer dogs

Bruce H. Grahn,* Eric S. Storey* and Catherine McMillan†

*Department of Small Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, 72 Campus Drive, Saskatoon, Saskatchewan S7N 5B4, Canada, †Box 579, Delisle, Saskatchewan S0E 0P0 Canada

Address communications to:

Bruce H. Grahn

Tel: +1-306-966-7083

Fax: +1-306-966-7174

e-mail: bruce.grahn@usask.ca

Abstract

The objectives of this study were to define the clinical syndrome of retinal dysplasia and persistent primary vitreous in Miniature Schnauzer dogs and determine the etiology. We examined 106 Miniature Schnauzers using a biomicroscope and indirect ophthalmoscope. The anterior and posterior segments of affected dogs were photographed. Four enucleated eyes were examined using routine light microscopy and scanning electron microscopy. A pedigree was constructed and related dogs were test-bred to define the mode of inheritance of this syndrome. Congenital retinal dysplasia was confirmed in 24 of 106 related Miniature Schnauzer dogs. Physical and postmortem examinations revealed that congenital abnormalities were limited to the eyes.




Biomicroscopic, indirect ophthalmoscopic, and neuro-ophthalmic examinations confirmed that some of these dogs were blind secondary to bilateral retinal dysplasia and detachment (nonattachments) ($n = 13$), and the remainder had generalized retinal dysplasia ($n = 11$). Fifteen of these dogs were also diagnosed with unilateral ($n = 9$) or bilateral ($n = 6$) persistent hyperplastic primary vitreous. Nutritional, infectious, or toxic etiologies were not evident on physical, postmortem, light microscopic, or transmitting and scanning electron microscopic examination of four affected Miniature Schnauzers. We examined the pedigree and determined that an autosomal recessive mode of inheritance was most likely. Three test-bred litters including those from affected parents, carrier and affected parents, and carrier parents confirmed this mode of inheritance. This study confirms that retinal dysplasia and persistent hyperplastic primary vitreous is a congenital abnormality that is inherited as an autosomal recessive condition in Miniature Schnauzers.

Key Words: inherited retinal dysplasia, Miniature Schnauzer, persistent hyperplastic primary vitreous, retinal detachment

INTRODUCTION

Retinal dysplasia is a common clinical syndrome in dogs. The clinical manifestations include single, multiple, or generalized gray retinal folds in the tapetal or non-tapetal fundus.¹ Retinal dysplasia has been morphologically categorized as single folds, geographic, and generalized forms, and the latter two may be associated with retinal detachment.² Retinal dysplasia is a congenital lesion, although a developmental form of geographic retinal dysplasia has been recently proposed.³ The pathogenesis of retinal dysplasia is complex and four developmental types have been proposed:⁴ (i) a hyperplastic extension of retina into abnormal sites away from the retinal pigment epithelium (RPE); (ii) within the

retina that is detached from the RPE; (iii) within the retina over regions devoid of RPE, i.e. colobomas; and (iv) within the retina *in situ* by a process which may involve the entire retina or a portion of it with no evidence of detachment from the RPE.⁴ Inherited retinal dysplasia in English Springer Spaniels has been the most thoroughly investigated of all the dog breeds. Whiteley reported an incomplete retinal differentiation, disruption of the outer limiting membrane, and formation of multiple rosettes within the nuclear and plexiform layers between days 45-50 of gestation in English Springer Spaniels.⁵ Multiple etiologies for retinal dysplasia have been identified in animals, including viruses and toxins, although most retinal dysplasia in dogs is inherited.⁶⁻⁸




PRA

- Progressive retinal atrophy: termine generico che comprende le **degenerazioni retiniche ereditarie**
- Malattie descritte in più di 100 razze canine (quadri clinici simili, ma diversa trasmissione, insorgenza e patogenesi);
- **PRA**: malattie di sviluppo (displasie) e malattie degenerative dei fotorecettori; quasi sempre cecità totale, **sempre esclusione** dalla riproduzione (soggetti malati, genitori e figli!);
- **Per alcune forme in alcune razze sono disponibili i test genetici**

PRA

- Insorgenza precoce:
- Iniziale arresto di sviluppo dei fotorecettori, seguito da rapida degenerazione (displasia dei fotorecettori, es. rcd);
- Trasmissione autosomica recessiva;
- Alterazioni oftalmoscopiche precoci.



PRA (PRCD) OPTIMAL SELECTION/OPTIGEN

- Insorgenza tardiva:
- RIESENSCHNAUZER
- *Progressive Rod-cone Degeneration (prcd)*: notevole variabilità nell'età di comparsa, nella progressione, nel grado e nella sede delle lesioni retiniche tra e nelle razze colpite;
- Rappresentano le forme più comuni;
-
- Degenerazione (tardiva) prima dei bastoncelli e poi dei coni;
- Di solito alterazioni oftalmoscopiche tardive;
- 27.27% portatori
- Geneticamente a rischio di sviluppare la malattia 2.27%
- Trasmissione autosomica recessiva.

PRA (PRCD)

- *Prcd (PRA)*: tratto autosomico recessivo;
- *Soggetto “Normale”*: OMOZIGOTE (due geni normali);
- *Soggetto “Portatore”*: ETEROZIGOTE (un gene normale e uno malato);
- *Soggetto “Affetto”*: OMOZIGOTE MUTANTE (due geni malati).
- TEST PER RIESENSCHNAUZER OFFERTO DA OPTIGEN (VETOGENE)/OPTIMAL SELECTION

Article

Whole Genome Sequencing of Giant Schnauzer Dogs with Progressive Retinal Atrophy Establishes *NECAP1* as a Novel Candidate Gene for Retinal Degeneration

Rebekkah J. Hitti ^{1,2,*}, James A. C. Oliver ¹, Ellen C. Schofield ¹ , Anina Bauer ³,
Maria Kaukonen ^{4,5,6} , Oliver P. Forman ⁷, Tosso Leeb ³ , Hannes Lohi ^{4,5,6},
Louise M. Burmeister ¹ , David Sargan ²  and Cathryn S. Mellersh ¹

¹ Kennel Club Genetics Centre, Animal Health Trust, Lanwades Park, Newmarket, Suffolk CB8 7UU, UK; jo@dwr.co.uk (J.A.C.O.); Ellen.Schofield@aht.org.uk (E.C.S.); Louise.Burmeister@aht.org.uk (L.M.B.); cathryn.mellersh@aht.org.uk (C.S.M.)

² Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK; drs20@cam.ac.uk

³ Institute of Genetics, University of Bern, 3001 Bern, Switzerland; anina.bauer@vetsuisse.unibe.ch (A.B.); toso.leeb@vetsuisse.unibe.ch (T.L.)

⁴ Department of Veterinary Biosciences, University of Helsinki, 00014 Helsinki, Finland; maria.kaukonen@helsinki.fi (M.K.); Hannes.Lohi@helsinki.fi (H.L.)

⁵ Department of Medical Genetics, University of Helsinki, 00014 Helsinki, Finland

⁶ Folkhälsan Research Center, 00290 Helsinki, Finland

⁷ Wisdom Health, Waltham-on-the-Wolds, Leicestershire LE14 4RS, UK; oliver.forman@effem.com

* Correspondence: rebekkah.hitti@aht.org.uk

Received: 15 April 2019; Accepted: 17 May 2019; Published: 21 May 2019







Abstract: Canine progressive retinal atrophies (PRA) are genetically heterogeneous diseases characterized by retinal degeneration and subsequent blindness. PRAs are untreatable and affect multiple dog breeds, significantly impacting welfare. Three out of seven Giant Schnauzer (GS) littermates presented with PRA around four years of age. We sought to identify the causal variant to improve our understanding of the aetiology of this form of PRA and to enable development of a DNA test. Whole genome sequencing of two PRA-affected full-siblings and both unaffected parents was performed. Variants were filtered based on those segregating appropriately for an autosomal recessive disorder and predicted to be deleterious. Successive filtering against 568 canine genomes identified a single nucleotide variant in the gene encoding NECAP endocytosis associated 1 (*NECAP1*): c.544G>A (p.Gly182Arg). Five thousand one hundred and thirty canids of 175 breeds, 10 cross-breeds and 3 wolves were genotyped for c.544G>A. Only the three PRA-affected GS were homozygous (allele frequency in GS, excluding proband family = 0.015). In addition, we identified heterozygotes belonging to Spitz and Dachshund varieties, demonstrating c.544G>A segregates in other breeds of German origin. This study, in parallel with the known retinal expression and role of *NECAP1* in clathrin mediated endocytosis (CME) in synapses, presents *NECAP1* as a novel candidate gene for retinal degeneration in dogs and other species.

Keywords: canine; dog; progressive retinal atrophy; PRA; retinal degeneration

PRA (NECAP1) AHT

- 3/7 manifestarono PRA a 4 anni di età
- Autosomica recessiva (madre e padre non affetti ad 8 e 11 anni , rispettivamente)
- Analizzati 5130 cani di 175 razze, 10 meticci e 3 lupi, inclusi 322 Riesenschнауzer
- Solo i 3 RS affetti erano omozigoti, entrambe i genitori erano eterozigoti
- 6 altri Riesenschнауzer eterozigoti identificati nella popolazione studiata
- Identificati soggetti eterozigoti in Spitz e Bassotti (quindi il gene segrega in altre razze di origine Tedesca)

PRA



PRA Type A

ORIGINAL ARTICLE

Photoreceptor Dysplasia: An Inherited Progressive Retinal Atrophy of Miniature Schnauzer Dogs

Charles J. Parshall¹, Milton Wyman², Susan Nitroy², Gregory Adand², Gustavo Aguirre^{2*}

A progressive retinal atrophy (PRA) affecting Miniature Schnauzer dogs is reported. Of the 287 individuals (148 female, 139 male) comprising the study population, 66 (23 percent) were affected (33 female, 33 male) and 221 animals (115 female, 106 male) were phenotypically normal. There was no sex predilection for the disease. Results of histologic and electroretinographic studies indicate that the disease is a new and different type of PRA, characterized by unique morphologic and functional deficits during rod and cone development. Accordingly, the disease has been termed photoreceptor dysplasia. Clinically, and particularly ophthalmoscopically, diagnosis is only practicable in very late stages of the disease. Electroretinography, however, can provide evidence of the disease in dogs at least as young as 8 weeks of age. Pedigree analysis and test-mating studies conclusively establish that inheritance is autosomal recessive. The gene symbol *pd* (for photoreceptor dysplasia) is assigned. (*Progress in Veterinary & Comparative Ophthalmology*, Vol. 1, No. 3, 1991, pp. 187-203; Key words: dog, electroretinography, photoreceptor dysplasia, progressive retinal atrophy.)

Generalized progressive retinal atrophy (PRA) is a clinical diagnostic category that groups together a variety of hereditary degenerative retinal diseases in domestic animals

cGMP-PDE, cyclic guanosine monophosphate phosphodiesterase; **erd**, early retinal degeneration; **ERG**, electroretinography; **ONL**, outer nuclear layer; **pd**, photoreceptor dysplasia; **PRA**, progressive retinal atrophy; **prcd**, progressive rod cone dysplasia type 1; **rcd2**, rod cone dysplasia type 2; **rd**, rod dysplasia

*Corresponding author, *The Veterinary Ophthalmology Clinic, 4030 Broadview Road, Sycamore Village, OH 44285-9686, USA.* ²*Veterinary Teaching Hospital, College of Veterinary Medicine, Ohio State University, 1915 Coffey Road, Columbus, OH 43210, USA.* ³*Section of Medical Genetics, School of Veterinary Medicine, University of Pennsylvania, 3950 Spruce Street, Philadelphia, PA 19104, USA*

(primarily in the dog). Although an increasing number of specific diseases within this category have been defined in several canine breeds, the diverse forms of PRA in the dog share certain clinical features.¹⁻⁹ Foremost among these similarities are a consistent ophthalmoscopic appearance of the retinal disease process, and an inexorable deterioration of retinal structure and function, leading to loss of vision. Furthermore, in all canine forms of PRA studied to date, the inheritance pattern has been autosomal recessive.^{1,2,4,6,7,10} Dissimilarities in manifestation of the disease, particularly among breeds, indicate that separate entities are grouped under the PRA rubric. These dissimilarities include differences in the age of emergence of clinical signs; in pathophysiology (dysplasia vs. degeneration); in the relative degree to which rod or cone cells are affected; and in biochemical abnormalities, such as deficiency of cyclic

PRA Type A SCHNAUZER NANO

- **Type A PRA o XLPRA2 : nella popolazione di S.N. si è rivelato una mutazione molto rara nella razza probabilmente perchè ormai eradicata o presente in bassissima frequenza. NON ha senso ora testare per questo gene**
- **It soon became clear that Type A PRA was an extremely rare disorder in the breed; in the 17 years the test has been available, not a single case of the disease was found out of 375 samples tested.**
- **Carriers < 1%**
- **Geneticamente a rischio <1%**
- **Cecità notturna già a 6-7 settimane e cecità a 2 anni di età**

Complex Structural *PPT1* Variant Associated with Non-syndromic Canine Retinal Degeneration

Leonardo Murgiano,^{**1,2} Doreen Becker,^{**1} Dina Torjman,^{*} Jessica K. Niggel,^{*} Ausra Milano,^{*} Cheryl Cullen,[§] Rui Feng,^{**} Fan Wang,^{**} Vidhya Jagannathan,^{**} Sue Pearce-Kelling,[†] Martin L. Katz,[¶] Tosso Leeb,^{**} and Gustavo D. Aguirre^{**2}

^{*}Department of Clinical Sciences & Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, [†]Institute of Animal Breeding and Husbandry, University of Kiel, Germany, [‡]OptiGen, LLC, Cornell Business & Technology Park, Ithaca, NY, [§]CullenWebb Animal Eye Specialists, Riverview, N.B. Canada, ^{**}Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ^{††}Department of Molecular Cardiology, Cleveland Clinic Lerner Research Institute, Cleveland, OH, ^{‡‡}Institute of Genetics, Vetsuisse Faculty, University of Bern, 3001 Bern, Switzerland, and ^{§§}Mason Eye Institute, University of Missouri School of Medicine Columbia, Missouri

ORCID ID: 0000-0002-8155-0041 (N.J.); 0000-0003-0553-4880 (T.L.)

ABSTRACT Rod and cone photoreceptors are specialized retinal neurons that have a fundamental role in visual perception, capturing light and transducing it into a neuronal signal. Aberrant functioning of rod and/or cone photoreceptors can ultimately lead to progressive degeneration and eventually blindness. In man, many rod and rod-cone degenerative diseases are classified as forms of retinitis pigmentosa (RP). Dogs also have a comparable disease grouping termed progressive retinal atrophy (PRA). These diseases are generally due to single gene defects and follow Mendelian inheritance. We collected 51 DNA samples from Miniature Schnauzers affected by PRA (average age of diagnosis $\sim 3.9 \pm 1$ years), as well as from 56 clinically normal controls of the same breed (average age $\sim 6.6 \pm 2.8$ years). Pedigree analysis suggested monogenic autosomal recessive inheritance of PRA. GWAS and homozygosity mapping defined a critical interval in the first 4,796,806 bp of CFA15. Whole genome sequencing of two affected cases, a carrier and a control identified two candidate variants within the critical interval. One was an intronic SNV in *HIVEP3*, and the other was a complex structural variant consisting of the duplication of exon 5 of the *PPT1* gene along with a conversion and insertion (named *PPT1_{del}*). *PPT1_{del}* was confirmed homozygous in a cohort of 22 cases, and 12 more cases were homozygous for the CFA15 haplotype. Additionally, the variant was found homozygous in 6 non-affected dogs of age higher than the average age of onset. The *HIVEP3* variant was found heterozygous ($n = 4$) and homozygous wild-type ($n = 1$) in cases either homozygous for *PPT1_{del}* or for the mapped CFA15 haplotype. We detected the wildtype and three aberrant *PPT1* transcripts in isolated white blood cell mRNA extracted from a PRA case homozygous for *PPT1_{del}* and the aberrant transcripts involved inclusion of the duplicated exon 5 and novel exons following the activation of cryptic splice sites. No neurological signs were detected among the dogs homozygous for the *PPT1_{del}* variant. Therefore, we propose *PPT1_{del}* as causative for a non-syndromic form of PRA (PRA_{non-synd}) that shows incomplete penetrance in Miniature Schnauzers, potentially related to the presence of the wild-type transcript. To our knowledge, this is the first case of isolated retinal degeneration associated with a *PPT1* variant.

KEYWORDS


progressive retinal atrophy
PRA
complex variant
retinal degeneration
whole genome sequencing
dog
palmitoyl protein thioesterase

PRA **Type B** SCHNAUZER NANO (OPTIGEN)

- TYPE B PRA (**PRAPPT1**): nuova variante che spiega numerosi casi di PRA nello S.N. (offerta da Optigen)
- This genetic variant accounts for 63% of Miniature Schnauzers affected with retinal degeneration in which the Type A form of the disease has been excluded, which indicates that at least one additional retinal disease locus exists in the breed.
- Soggetti omozigoti per questa variante **hanno l'86% di probabilità di sviluppare la malattia ; comunque il 14% degli omozigoti per questo gene non sviluppa la malattia entro i 7 anni** forse per “penetranza” incompleta del gene o perchè la variante in oggetto è un marker genetico che si trova solo vicino alla vera mutazione causale
- Ereditarietà **autosomica recessiva**

PRA SCHNAUZER NANO

- The average age of the affected dogs was 3.961 years of age. In fact, seven dogs were older, with clinical disease not diagnosed until 4.5-6.5 years of age.
- Di 76 cani con PRA il 55% erano omozigoti per il Tipo B
- Dei rimanenti 45%, l'11% erano eterozigoti e il 34% erano clear per il Tipo B
- Questo significa che esiste **ALMENO** una ulteriore forma di PRA (oltre A e B) presente nella razza. **Quindi:** *esistono anche soggetti con mutazioni diverse (sono affetti, ma con test negativo!) (al contrario possibile anche cani con test positivo, ma senza sviluppo della malattia!).*



Comparazione Italia-Panel ECVO (D,A,O,DK,N)

Italia Riesenschneider

2013/2019 ECVO, 2014/2018 FSA

- 27 esaminati (14 affetti)
51.8%
- 2 atresia punto lacrimale
7.4%
- 9 cataratte (5 subcaps
pol post) 33.3%
- 2 PHPV/PHTVL 1° grado
7.4%
- 5 displasia retinica
mf/geografica 18.5%
- 1 PRA 3.7%

Panel ECVO Riesenschneider

- 840 esaminati (178 affetti)
21%
- 2 atresia punto lacrimale
0.23%
- 67 cataratte (polare
posteriore) 7.9%
- 7 PHPV/PHTVL 1° grado
0.83%
- 11 displasia retinica
mf/geografica 1.3%
- 15 PRA 1.78%

Comparazione Italia-Panel Svedese

Italia Riesenschnauzer 2013/2019 ECVO, 2014/2018 FSA

- 27 esaminati (14 affetti)
51.8%
- 2 atresia punto lacrimale
7.4%
- 9 cataratte (5 subcaps pol
post) 33.3%
- 2 PHPV/PHTVL 1° grado
7.4%
- 5 displasia retinica
mf/geografica 18.5%
- 1 PRA 3.7%

Panel Svedese Riesenschnauzer 2010/2015

- 43 esaminati (7 affetti)
16.2%
- 3 Cataratte 6.97%
- 1 Displasia retinica 2.32%
- 1 PRA 2.32%

Comparazione Italia-Panel Finlandese

Italia Riesenschnauzer 2013/2019 ECVO, 2014/2018 FSA

- 27 esaminati (14 affetti)
51.8%
- 2 atresia punto lacrimale
7.4%
- 9 cataratte (5 subcaps pol
post) 33.3%
- 2 PHPV/PHTVL 1° grado
7.4%
- 5 displasia retinica
mf/geografica 18.5%
- 1 PRA 3.7%

Panel Finlandese ECVO Riesenschnauzer 2014/2019

- 284 esaminati (40 affetti)
14%
- 16 atresia punto
lacrimale 14.08%
- 3 cataratte (2 posteriore
polare) 1.05%
- 7 PHPV/PHTVL 1° grado
2.46%
- 11 Displasia retinica
mf/geografica 3.8%

Comparazione Italia-USA

Italia Riesenschnauzer 2013/2019 ECVO, 2014/2018 FSA

- 27 soggetti esaminati (14 affetti) 51.8%
- 2 atresia punto lacrimale 7.4%
- 9 cataratte (5 subcaps pol post) 33.3%
- 2 PHPV/PHTVL 1° grado 7.4%
- 5 displasia retinica mf/geografica 18.5%
- 1 PRA 3.7%

Riesenschnauzer USA 2014-2018

- 379 soggetti esaminati (82 affetti) 21.6%
- 1 atresia punto lacrimale 0.3%
- 20 cataratte (5 corticale posteriore) 5.3%
- NO PHPV/PHTVL
- 7 displasia retinica mf/geografica 1.8%
- NO PRA

Comparazione Italia-Panel ECVO (D,A,O,DK,N)

Italia Zwergschnauzer

2013/2019 ECVO, 2014/2018 FSA

- 177 esaminati (62 affetti)
35%
- 7 atresia punto lacrimale
3.95%
- 13 cataratte (5 corticale
posteriore) 7.34%
- 7 displasia retinica
mf/geografica 3.95%

Panel ECVO Zwergschnauzer

- 2508 esaminati (466
affetti) 18.5%
- 8 atresia punto lacrimale
0.31%
- 101 cataratte (57
corticale) 4.02%
- 3 displasia retinica
mf/geografica 0.11%
- 38 PRA 1.5%

Comparazione Italia-Panel Svedese

Italia Zwergschnauzer
2013/2019 ECVO, 2014/2018 FSA

- 177 esaminati (62 affetti) 35%
- 7 atresia punto lacrimale 3.95%
- 13 cataratte (5 corticale posteriore) 7.34%
- 7 displasia retinica mf/geografica 3.95%

Panel Svedese Zwergschnauzer
2010/2018

- 1683 esaminati (157 affetti) 9.3%
- 1 atresia punto lacrimale 0.059%
- 58 cataratte (26 corticale e post.polare) 3.44%
- No displasia
- 13 PRA 0.77%

Comparazione Italia-Panel Finlandese

Italia Zwergschnauzer
2013/2019 ECVO, 2014/2018 FSA

- 177 esaminati (62 affetti)
35%
- 7 atresia punto lacrimale
3.95%
- 13 cataratte (5 corticale
posteriore) 7.34%
- 7 displasia retinica
mf/geografica 3.95%

Panel Finlandese ECVO
Zwergschnauzer 2014/2019

- 902 esaminati (183
affetti) 20.2%
- 14 atresia punto
lacrimale 1.55%
- 17 cataratte 1.88%
- 1 displasia retinica 0.11%
- 4 PRA 0.44%

Comparazione Italia-USA

Italia Zwergschnauzer
2013/2019 ECVO, 2014/2018 FSA

- 177 esaminati (62 affetti)
35%
- 7 atresia punto lacrimale
3.95%
- 13 cataratte (5 corticale
posteriore) 7.34%
- 7 displasia retinica
mf/geografica 3.95%

Zwergschnauzer USA 2014-2018

- 5843 soggetti esaminati
(741 affetti) 13.5%
- 2 atresia punto lacrimale
0.034%
- 244 cataratte 4.2%
- 3 PHPV/PHTVL 0.1%
- 6 displasia retinica
mf/geografica 0.1%
- 8 PRA 0.1%

Comparazione Italia-Panel ECVO (D,A,O,DK,N)

Italia Schnauzer 2013/2019

ECVO, 2014/2018 FSA

- 21 soggetti esaminati (4 affetti) 19%
- 1 PPM iride-iride 4.76%
- 3 cataratte (2 corticale post, 1 subcaps pol post) 14.2% (NERI)

Panel ECVO Schnauzer

- 398 soggetti esaminati (48 affetti) 12%
- 2 PPM 0.5%
- 22 cataratte (7 corticale, 4 posteriore polare) 5.5%
- 2 PRA 0.5%

Comparazione Italia-Panel Svedese

Italia Schnauzer 2013/2019
ECVO, 2014/2018 FSA

- 21 soggetti esaminati (4 affetti) 19%
- 1 PPM iride-iride 4.76%
- 3 cataratte (2 corticale post, 1 subcaps pol post) 14.2% (NERI)

Panel Svedese Schnauzer 2010-
2017

- 10 soggetti esaminati (6 affetti) 60%
- 1 PPM 10%
- 3 cataratte (2 corticale) 30%
- 1 PRA 10%

Comparazione Italia-Panel Finlandese

Italia Schnauzer 2013/2019
ECVO, 2014/2018 FSA

- 21 soggetti esaminati (4 affetti) 19%
- 1 PPM iride-iride 4.76%
- 3 cataratte (2 corticale post, 1 subcaps pol post) 14.2% NERI

Panel Finlandese ECVO
Schnauzer 2014/2019

- 151 soggetti esaminati (13 affetti) 8.6%
- 3 cataratte (1 corticale, 1 polare post) 1.98% NERI

Comparazione Italia-USA

Italia Schnauzer 2013/2019

ECVO, 2014/2018 FSA

- 21 soggetti esaminati (4 affetti) 19%
- 1 PPM iride-iride 4.76%
- 3 cataratte (2 corticale post, 1 subcaps pol post) 14.2% NERI

Schnauzer USA 2014-2018

- 657 soggetti esaminati (105 affetti) 15.9%
- 2 PPM (1 iride-iride, 1 iride –cornea) 0.4%
- 37 cataratte 5.6%

Comparazione Italia-Panel

ECVO (D,A,O,DK,N)

Italia Zwergpinscher 2013/2019

ECVO, 2014/2018 FSA

- 41 soggetti esaminati (9 affetti) 21.9%
- 4 PPM (1 iride-iride, 3 iride lente) 9.75%
- 1 cataratta (corticale polare posteriore) 2.43%
- 1 Displasia retinica mf/geografica 2.43%
- 2 PRA 4.87%
- NO LL ???

Panel ECVO Zwergpinscher

- 1259 soggetti esaminati (236 affetti) 18.7%
- 72 PPM (67 iride-iride, 15 iride-lente) 5.71%
- 47 cataratte (35 corticale, 9 post polare) 3.73%
- No displasia
- 5 PRA 0.39%
- 5 LL 0.39%

Comparazione Italia-Panel Svedese

Italia Zwergpinscher 2013/2019
ECVO, 2014/2018 FSA

- 41 soggetti esaminati (9 affetti) 21.9%
- 4 PPM (1 iride-iride, 3 iride lente) 9.75%
- 1 cataratta (corticale polare posteriore) 2.43%
- 1 Displasia retinica mf/geografica 2.43%
- 2 PRA 4.87%
- NO LL ???

Panel Svedese Zwergpinscher
2010-2018

- 574 soggetti esaminati (174 affetti) 30.3%
- 6 PPM 1.04%
- 24 cataratte (11 corticale, 6 polare posteriore) 4.18%
- No displasia
- 5 PRA 0.87%
- NO LL

Comparazione Italia-Panel Finlandese

Italia Zwergpinscher 2013/2019
ECVO, 2014/2018 FSA

- 41 soggetti esaminati (9 affetti) 21.9%
- 4 PPM (1 iride-iride, 3 iride lente) 9.75%
- 1 cataratta (corticale polare posteriore) 2.43%
- 1 Displasia retinica mf/geografica 2.43%
- 2 PRA 4.87%
- NO LL ???

Panel Finlandese ECVO
Zwergpinscher 2014/2019

- 425 soggetti esaminati (23 affetti) 5.4%
- 2 PPM iride-iride 0.47%
- 9 cataratte (4 corticali, 4 posteriore polare) 2.11%
- 1 Displasia retinica mf 0.23%
- NO PRA
- NO LL
- 6 PHPV/PHTVL (4 1° grado, 2 2°-6° grado) 1.41%

Comparazione Italia-USA

Italia Zwergpinscher 2013/2019 ECVO, 2014/2018 FSA

- 41 soggetti esaminati (9 affetti) 21.9%
- 4 PPM (1 iride-iride, 3 iride lente) 9.75%
- 1 cataratta (corticale polare posteriore) 2.43%
- 1 Displasia retinica mf/geografica 2.43%
- 2 PRA 4.87%
- NO LL ???

Zwergpinscher USA 2014-2018

- 209 soggetti esaminati (64 affetti) 30.6%
- 6 PPM 2.9%
- 16 cataratte 7.7%
- 1 Displasia retinica mf 0.5%
- NO PRA
- NO LL

Come indagare le Malattie oculari




Lampada a fessura



Oftalmoscopia indiretta

Quali Riferimenti? (ECVO Manual 2017 (www.ecvo.org)/ ACVO Blue Book 2018)




ECVO Manual

for

Presumed Inherited Eye Diseases

in

Dogs and Cats



ECVO HED Committee, 2013

The image shows the title page of the 'ECVO Manual'. At the top is the ECVO logo, which consists of the letters 'ECVO' in a stylized font with a circular graphic element. Below the logo is the title 'ECVO Manual' in a large, bold, black serif font. Underneath the title are the words 'for', 'Presumed Inherited Eye Diseases', 'in', and 'Dogs and Cats' in a smaller, bold, black serif font. At the bottom of the page, there are four small, square images arranged horizontally. From left to right: a close-up of a dog's eye with a white lesion on the cornea; a fundus photograph showing a reddish, inflamed area; a close-up of a dog's eye with a blue sclera; and a fundus photograph showing a red spot on the retina. Below these images is the text 'ECVO HED Committee, 2013' in a bold, black serif font.

Chi?

- ***Diplomati ECVO***: con certificazione internazionale ECVO (attualmente 5 in Italia);
- ***Accreditati FSA***: con certificazione nazionale FSA (attualmente 30 in Italia);
- ***Abilitati ESE***: con certificazione internazionale ECVO (attualmente nessuno in Italia);
- ***Accreditati ENCI***: con certificazione ENCI (attualmente 8 in Italia).



CERTIFICATO DI VISITA OCULISTICA PER LA DIAGNOSI DELLE MALATTIE OCULARI DI PROVATA O PRESUNTA ORIGINE EREDITARIA NEL CANE

OFFICIAL CERTIFICATE OF EYE EXAMINATION FOR THE DIAGNOSIS OF PROVEN OR PRESUMED INHERITED EYE DISEASES IN DOGS

VISITA OCULISTICA DEL: _____ CERTIFICATO N° _____ ESAMINATORE Dott. _____ n° aut FSA _____

CANE/DOG _____

Nome/Name _____ Razza/Breed _____

Sesso/sex _____ Nato il/date of birth _____ Colore/color _____ Microchip _____

Tatuaggio/tag no _____ Test DNA _____ no _____ si/yes _____ Data/date _____ Risultato/result _____

Esaminato/checked _____ Data/date _____ Risultato/result: esente/unaffected _____ affetto/affected _____ non def-sosp/undet.-sus. _____

PROPRIETARIO / OWNER _____

Proprietario / owner _____

Indirizzo / address _____

Visita, protocollo obbligatorio: Midriatico _____ Oftalmoscopia indiretta _____ Biomicroscopia binoculare > 10x _____ Esame pre-dilatazione x razza _____

Altre indagini: Esame pre-dilatazione _____ Oftalmoscopia diretta _____ Gonioscopia _____ Tonometria _____ Altro _____

Risultati per le malattie ritenute congenite/ereditarie

Risultati per le malattie ritenute ereditarie


Esante*	Non definito*	Affetto**	Esante*	Sospetto***	Affetto**
1. Mem. Pupil. Persistens (PPM)	<input type="checkbox"/>	<input type="checkbox"/>	9. Entropion/trichiasi	<input type="checkbox"/>	<input type="checkbox"/>
2. Pers. Hyp.T. Vas.L/Pr. Vit. (PHTV/PPHV)	<input type="checkbox"/>	<input type="checkbox"/>	10. Ectropion/macroblectaron	<input type="checkbox"/>	<input type="checkbox"/>
3. Cataratta (congenita)	<input type="checkbox"/>	<input type="checkbox"/>	11. Distichiasi/ciglia ectopiche	<input type="checkbox"/>	<input type="checkbox"/>
4. Retina: displasia (RD)	<input type="checkbox"/>	<input type="checkbox"/>	12. Distrofia corneale	<input type="checkbox"/>	<input type="checkbox"/>
5. Ipoplasia n.o/ Micropapilla	<input type="checkbox"/>	<input type="checkbox"/>	13. Cataratta (non congenita)	<input type="checkbox"/>	<input type="checkbox"/>
6. Collie Eye Anomaly (CEA)	<input type="checkbox"/>	<input type="checkbox"/>	14. Lussazione primaria lente	<input type="checkbox"/>	<input type="checkbox"/>
7. Altro _____	<input type="checkbox"/>	<input type="checkbox"/>	15. Degenerazione retinica (PRA)	<input type="checkbox"/>	<input type="checkbox"/>
8. Anomalia L. Pectinatum	<input type="checkbox"/>	<input type="checkbox"/>	16 Altro _____	<input type="checkbox"/>	<input type="checkbox"/>

*Non affetto, non si evidenziano alterazioni caratteristiche di occupate ereditarie. **Affetto, si evidenziano tali alterazioni. ***Sospeso, non si evidenziano alterazioni che potrebbero dipendere da una occupata ereditaria ma non sono del tutto patognomiche. Riesaminare l'animale a distanza di _____ mesi. ****Vengono alterazioni di lieve entità, si sospetta l'insorgenza di un'occupata ereditaria. Riesaminare l'animale a distanza di _____ mesi.

MALATTIA N° _____ Gonioscopia: anomalia L. Pectinatum lieve _____ moderata _____ grave _____

DESCRIZIONE DEL QUADRO CLINICO _____

Nota: affetto da _____ basi ereditarie non definite in questa razza



DI CHIA RAZIONE DEL PROPRIETARIO Dichiaro che: a) i dati sopra riportati sono corretti e si riferiscono al mio cane esaminato in data ed in b) autorizzo FSA a tenere e conservare nel proprio archivio copia del certificato e utilizzarlo a scopo scientifico-epidemiologico c) ai sensi dell'art. 13 D. Lgs 30 Giugno 2003, n. 196, consento il trattamento dei dati personali riportati su questo certificato, nei limiti indicati dalla legge

Data _____
Firma del proprietario o di un familiare _____

DI CHIA RAZIONE DEL VETERINARIO Confermo che il cane ha il microchip tatuaggio n° _____ indicato sul Certificato genelogico e che da questa visita effettuata secondo il protocollo FSA è stato dichiarato: esente/unaffected _____ affetto/affected _____ non definito/undetermined _____ sospetto/suspicious _____ da malattie oculari di provata o presunta origine ereditaria/by proven or presumed inherited eye diseases

Data _____
Firma e timbro del certificatore _____

Questo certificato è stato redatto in base alle attuali conoscenze scientifiche e facendo riferimento alle liste delle occupate ereditarie o presunte tali pubblicate dall'European and American College of Veterinary Ophthalmologists. Lo stato di "affetto" determina l'esclusione dalla riproduzione per alcune malattie oculari ma non per tutte (vedasi indicazioni per ciascuna razza). Non si autorizza la diffusione di informazioni pubblicitarie con riferimenti al nome del medico veterinario certificatore.

Registrazione FSA: pratica FSA/HED n. _____ Data: _____ Timbro FSA _____

ECVO Certificato di visita oculistica / Certificate of eye examination / European College of Veterinary Ophthalmologists

Registrazione per l'Italia: FSA - Fondazione Salute Animale (Animal Health Foundation) via Treccani 20 26100 Cremona, Italia Tel: +39 0372 402211 Fax: +39 0372 402230

ECVO (reg. no. 0006007) O-I No. 0006007

Animale
Nome _____ Razza _____
Sesso _____ Nato il/date of birth _____ Colore/color _____ Microchip _____
Tatuaggio/tag no _____ Test DNA _____ no _____ si/yes _____ Data/date _____ Risultato/result _____
Esaminato/checked _____ Data/date _____ Risultato/result: esente/unaffected _____ affetto/affected _____ non def-sosp/undet.-sus. _____

Proprietario/AGENTE
Nome _____ Test DNA _____ si _____ no _____
Indirizzo _____
Firma del proprietario/ agente _____

L'ho sottoscritto in base alle regole del sistema di certificazione nazionale e confermo che l'animale portato in visita è quello sopra descritto. La firma in data e luogo sopra i risultati sono disponibili per pubblicazione ufficiale e per altri usi approvati dall'ECVO.

The visiting vet agrees to the rules of the national scheme and confirms that the animal submitted for examination is the one described above. Signature above means that the results are available for official publication and other ECVO approved uses.

Visita oculistica
Data _____
Malattie minime: Midriatico, Oftalmoscopia indiretta e Biomicroscopia binoculare > 10x. Esame pre-dilatazione x razza. Esame pre-dilatazione. Gonioscopia (senza midriatico).
Opzioni: Tonometria (sempre con midriatico).
Se è stato un altro risultato, questo stampo ha senso solo se accompagnato da una descrizione verbale.

Descrizione
Occhio destro (OD) / left eye: _____
Occhio sinistro (OS) / right eye: _____

Malattia oculare no.: _____ lieve _____ moderata _____ grave _____

Nota: affetto
Non si evidenziano alterazioni caratteristiche di occupate ereditarie. Affetto, si evidenziano tali alterazioni. Sospeso, non si evidenziano alterazioni che potrebbero dipendere da una occupata ereditaria ma non sono del tutto patognomiche. Riesaminare l'animale a distanza di _____ mesi. Vengono alterazioni di lieve entità, si sospetta l'insorgenza di un'occupata ereditaria. Riesaminare l'animale a distanza di _____ mesi.

Risultati per le malattie ritenute ereditarie / results for the presumed inherited eye diseases	risultato per 12 mesi / results valid for 12 months			risultati validi per 12 mesi / results valid for 12 months		
	Esante	Non definito	Affetto	Esante	Non definito	Affetto
1. Persistent Pupillary Membrane (PPM)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Persistent Hypertensive Tunica Vasculosa Lenta/Primary Vascular Leucoma (PHTV/PPHV)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Cataratta (congenita)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. Displasia della retina (RD)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Ipoplasia / Micropapilla	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Collie Eye Anomaly (CEA)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. Altro (altro)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. Anomalia L. Pectina (P.L.A. only after pre-dilatation)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9. Entropion/Trichiasis	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10. Ectropion/Macroblectaron	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11. Distichiasis/Ciglia ectopiche	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
12. Distrofia corneale	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
13. Cataratta (non congenita)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
14. Lussazione lente (primaria)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
15. Degenerazione retinica (PRA)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
16. Altro	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Legenda:
"Esante" significa che non si evidenziano alterazioni caratteristiche di presunte occupate ereditarie, mentre "Affetto" significa che si evidenziano tali alterazioni. "Non definito" significa che non si evidenziano alterazioni che potrebbero dipendere da una occupata ereditaria ma non sono del tutto patognomiche, mentre "Sospetto" significa che si evidenziano alterazioni di lieve entità, si sospetta l'insorgenza di un'occupata ereditaria, ma non si evidenziano alterazioni che potrebbero dipendere da una occupata ereditaria ma non sono del tutto patognomiche. Riesaminare l'animale a distanza di _____ mesi. Vengono alterazioni di lieve entità, si sospetta l'insorgenza di un'occupata ereditaria. Riesaminare l'animale a distanza di _____ mesi.

Il veterinario accetta le regole del sistema di certificazione nazionale e conferma che l'animale portato in visita è quello sopra descritto. La firma in data e luogo sopra i risultati sono disponibili per pubblicazione ufficiale e per altri usi approvati dall'ECVO.

The visiting vet agrees to the rules of the national scheme and confirms that the animal submitted for examination is the one described above. Signature above means that the results are available for official publication and other ECVO approved uses.

Il sottoscritto ha letto e approvato l'animale sopra descritto per le indagini sulle occupate ereditarie con i risultati riportati.

I sottoscritto ha letto e approvato l'animale sopra descritto per le indagini sulle occupate ereditarie con i risultati riportati.

Dr Adolfo Guandini
Sede: Via C. Cav. n. 10 - 26100 Cremona - Tel. 0372 402211
50000 Via S. Giovanni 51-53 00137 RM
Tel. 062200007 - Cell. 336789432
C.F. 020017016240501X
P.IVA 02139750541
Forma societaria: Associazione di T.S.V.O.
Indirizzo e-mail: adolfo@ecvo.it

Quando?

- Nei soggetti ***Riproduttori***: visite effettuate a 1 anno di età e ripetute annualmente fino ai 6-7 anni;
- **Nei soggetti non Riproduttori, tre volte nella vita (1,3,7 anni di età);**

Condotta di Allevamento Riesenschнауzer

- **VET ADVICE (CAP. 8 Manuale ECVO)**

atresia punto lacrimale 7.4%- OPTIONAL

cataratte 33.3%- **NO BREEDING from the affected animal**

PHPV/PHTVL 1° grado 7.4%- OPTIONAL

Displasia retinica mf/geografica 18.5%- OPTIONAL (?) **DA
DISCUTERE**

PRA 3.7%- **NO BREEDING from the affected animal, its parents
or offsprings**

Condotta di Allevamento Zwergschnauzer

- **VET ADVICE (CAP. 8 Manuale ECVO)**

atresia punto lacrimale 3.95%- OPTIONAL

cataratte 7.34%- **NO BREEDING** from the affected animal

displasia retinica mf/geografica 3.95%- OPTIONAL

PRA - NO BREEDING from the affected animal, its parents or offsprings

Condotta di Allevamento Schnauzer

- VET ADVICE (CAP. 8 Manuale ECVO)

PPM iride-iride 4.76%- OPTIONAL

Cataratte 14.2%- NO BREEDING from the affected animal

PRA - NO BREEDING from the affected animal, its parents or offsprings

Condotta di Allevamento

Zwergpinscher

- VET ADVICE (CAP. 8 Manuale ECVO)

PPM iride-iride - OPTIONAL, iride-lente - NO BREEDING from the affected animal 9.75%

Cataratta 2.43% - NO BREEDING from the affected animal

Displasia retinica mf/geografica 2.43% - OPTIONAL

PRA 4.87% - NO BREEDING from the affected animal, its parents or offsprings

LL - NO BREEDING from the affected animal, its parents or offsprings

A cosa servono i certificati ed i test genetici?

- 1) allevamento “sano”; beneficio per CANI, Allevatori e Proprietari
- 2) “movimento” internazionale di cani; adeguamento a standard più elevati di lavoro
- 3) studi epidemiologici

Veterinary Ophthalmology (2017) 1–6

DOI:10.1111/veop.12442

Epidemiology of ocular disorders presumed to be inherited in three small Italian dog breeds in Italy

Adolfo Guandalini,* Nicola Di Girolamo,*†,‡ Daniela Corvi,* Daniele Santillo,* Valentina Andreani* and Barbara Pinzo*

*Department of Ophthalmology, Centro Veterinario Specialistico (CVS), Via Sanzio Giacomini 51/53, 00137 Rome, Italy, and †EBMS/6, Via Sigmund Freud 24, Comano, Italy

Address correspondence to:
N. Di Girolamo
Tel.: (+39) 32 92003 570
Fax (+39) 06 82 05 9207
e-mail: nicoladigg@gmail.com

Abstract

Objective To describe the prevalence and the types of eye disorders that are known or presumed to be inherited (KP-HED) in three small Italian dog breeds.

Animals Three small Italian dog breeds: Maltese, Bolognese, and Italian Greyhound. **Procedures** All dogs of the breeds selected for this prospective observational study that underwent a complete ophthalmic examination between 1994 and 2015 were included. General and proportional KP-HED prevalence with 95% confidence intervals were reported.

Results Three hundred and six of 462 dogs were affected by at least one KP-HED (66.2%; 95% CI: 61.8%–70.4%). In the entire population, the five most common KP-HED were cataract ($n = 122$; rate on the total number of KP-HED: 31.4%), entropion ($n = 56$; 14.4%), keratoconjunctivitis sicca ($n = 33$; 8.5%), retinal dysplasia ($n = 24$; 6.2%), and persistent pupillary membrane (iris to iris) ($n = 21$; 5.4%). The most common KP-HED in each breed were cataracts in the Maltese (35.1%) and in the Bolognese (24.2%), and presentation of vitreous in the anterior chamber in the Italian Greyhound (46.7%).

Conclusions Clinicians should be aware of KP-HED that commonly affect three small Italian dog breeds. Breed standards should be reconsidered, and breeding programs should be directed at limiting such disorders.

Key Words: cataract, hereditary, known and presumed-hereditary eye diseases, PIED, selection, vitreous degeneration

INTRODUCTION

Inherited eye diseases significantly impair vision in humans and animals.^{1–4} As of 2015, 278 genes and loci have been associated with retinal disorders in humans.⁵ The identification and characterization of inherited eye disorders are critical for the diagnosis, prevention, and treatment of such disorders.^{6,7}

Several inherited and presumed to be inherited eye disorders have been described in purebred dogs.^{8–11} Until the genetic basis of an ocular disorder is properly defined, ocular disorders that are suspected to have a genetic basis are defined as ‘known and presumed-hereditary eye diseases’ (KP-HED). An ocular disorder is defined as ‘presumed to be inherited’ when 1: it is observed more frequently in one breed compared with other breeds; 2: its incidence increases in a breed; 3: it is observed more

frequently within related dogs of a certain breed; 4: it has a characteristic appearance and location; 5: it has a characteristic age of onset and course of progression; and 6: it is similar to an entity which has been proven to be inherited in other breeds.¹⁰

Italy is homeland of sixteen dog breeds.¹² These include three small-sized breeds: Italian Greyhound (Fédération Cynologique Internationale (FCI) code 200), which standard has been definitively accepted in 1956 and is included in the group 10, section ‘Short-haired Sighthounds’, Maltese (FCI code: 63), accepted in 1955, and Bolognese (FCI code: 196), accepted in 1956.¹³ Both these two latter breeds are included in group 9, ‘Companion and Toy Dogs’ under the section ‘Bichons and related breeds’.¹² Scientific knowledge about KP-HED in these breeds is limited. The 2017 publication of the Hereditary Eye Disease (HED) Committee of the ECVO reports data on the

Veterinary Ophthalmology (2017) 20, 5, 420–426

DOI:10.1111/veop.12442

Epidemiology of ocular disorders presumed to be inherited in three large Italian dog breeds in Italy

Adolfo Guandalini,* Nicola Di Girolamo,*†,‡ Daniele Santillo,* Valentina Andreani,* Roberta Corvi,*‡, Marina Bandini* and Claudio Peruccio‡

*Department of Ophthalmology, Centro Veterinario Specialistico (CVS), Via Sanzio Giacomini 53, Rome 00137, Italy; †Department of Veterinary Science, University of Bologna, Via Tiberio di Sopra, 50, Ozzano dell'Emilia, Bologna 40064, Italy; ‡Department of Veterinary Science, University of Teramo, Sanzio Giacomini 13 mc, Pieve d'Alino, Teramo 64100, Italy; and §Ophthalmology, Centro Veterinario Terzano, Lungo Dora Pieve Cellata 147, Teramo 64153, Italy

Address communications to:
N. Di Girolamo
Tel.: (+39) 32 92003 570
Fax (+39) 06 82 05 9207
e-mail: nicoladigg@gmail.com

The authors declare any financial interest with companies that are the subject of the present research or with companies that manufacture competing products.

Abstract

Objective To describe the epidemiology and the types of eye disorders that are presumed to be inherited (PIED) in three large Italian dog breeds.

Animals Three large Italian dog breeds: Neapolitan Mastiff (FCI code: 197), Maremma Sheepdog (FCI code: 201), and Italian Cane Corso dog (FCI code: 343).

Procedures All dogs that underwent a complete ophthalmic examination between 1992 and 2012 were included in this prospective observational study. The prevalence of eye disorders with 95% confidence intervals was reported for presumed healthy dogs and for dogs referred to a veterinary center for an ophthalmic consultation. Univariate and multivariate logistic regression techniques were used to generate odds ratios.

Results Of 605 dogs examined during the study period, 351 dogs were affected by at least one PIED (58%; 95% CI: 54–62%). The prevalence of PIED was significantly lower in dogs presented for ophthalmic examination (53.8%) as compared to presumed healthy dogs (62.2%) (OR: 1.4, 95% CI: 1.02–1.9, $P = 0.037$). Also after multivariate adjustment for the period of observation, the odds of Neapolitan Mastiff (92.1%; OR: 21.4; 95% CI: 11.1–41.4) and of Cane Corso (57.7%; OR: 2.5; 95% CI: 1.7–3.6) suffering a PIED were greater than the Maremma Sheepdog (35.4%). The most common PIED in each breed were entropion (24.3% of all the PIED) in the Neapolitan Mastiff, entropion (36.6%) in the Corso dog, and cataract (27.9%) in the Maremma Sheepdog.

Conclusions Clinicians should be aware that three large Italian dog breeds frequently suffer PIED. Breed standards should be reconsidered, and breeding programs should be directed at limiting such disorders.

Key Words: breed, entropion, entropion, epidemiology, inherited, predisposition

INTRODUCTION

Inherited eye diseases significantly impair vision in humans and animals.^{1–4} As of 2015, 278 genes and loci have been associated with retinal disorders in humans.⁵ The identification and characterization of inherited eye disorders are critical for the diagnosis, prevention, and treatment of such disorders.^{6,7}

Several inherited and presumed to be inherited eye disorders have been described in pure-bred dogs.^{8–11} Until the genetic basis of an ocular disorder is properly defined, ocular disorders that are suspected to have a genetic basis are defined as ‘presumed to be inherited eye disorders’

(PIED). An ocular disorder is defined as ‘presumed to be inherited’ when it is (i) observed more frequently in one breed compared with other breeds; (ii) observed more frequently within related dogs of a certain breed; (iii) with characteristic appearance and location; (iv) with characteristic age of onset and course of progression; and (v) similar to an entity which has been proven to be inherited in other breeds.¹⁰

Italy is the homeland of sixteen dog breeds.¹² These include three large-size breeds: the Neapolitan Mastiff (Fédération Cynologique Internationale (FCI) code: 197), the Maremma Sheepdog (FCI code: 201), and the Italian Cane Corso dog (FCI code: 343).¹³ Scientific knowledge about

Conclusioni

- Importanza della **prevenzione** e della diagnosi precoce;
- Importanza delle **visite** oculistiche e dei **tests** genetici (l'uno non esclude l'altro); Possono esserci **mutazioni diverse** per la stessa malattia!;
- Per moltissime patologie **non esiste** ancora il test genetico!;
- Importanza nella **collaborazione** tra veterinari ed allevatori;
Unione di intenti, fiducia e serietà reciproca!

DOMANDE ?

